Dr. Richardson on Preliminary Data With Belantamab Mafodotin in Multiple Myeloma
December 12th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the preliminary data that has been reported with belantamab mafodotin (GSK2857916) in multiple myeloma.
Addressing Belantamab Mafodotin-Related Corneal Events in Myeloma is Key to Continuing Treatment
December 6th 2019Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.
Novel Therapies Surge Forward in Relapsed/Refractory Multiple Myeloma
November 26th 2019Thomas G. Martin, MD, provides insight into novel therapies under evaluation in relapsed/refractory multiple myeloma and the steps that need to be taken prior to and upon the use of these approaches in clinical practice.